Jiangsu Vcare Completes First Patient Enrollment in Phase II Clinical Trial of VC005 Topical Gel for Mild-to-Moderate Atopic Dermatitis
Published Time:
2025-04-28 18:00
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful enrollment of the first participant in its Phase II clinical trial for VC005 topical gel, a self-developed next-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD). The trial aims to evaluate the efficacy of VC005 gel in adult patients with mild-to-moderate AD, providing a critical data for dose selection in future clinical studies and further assesses the drug's safety profile.
In the Phase I clinical study completed in July, 2024, VC005 gel demonstrated excellent safety and significant efficacy. Compared to similar topical drugs already on the market, VC005 exhibits much lower systemic exposure in humans, potentially offering superior long-term safety for patients.
Additionally, the Phase III clinical trial for VC005 tablets, an oral formulation targeting moderate-to-severe AD, is currently enrolling participants. Preliminary results show significant patient benefits and a favorable safety profile.
About VC005
VC005 is a novel, potent, and highly selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, the drug is designed for the treating inflammatory and autoimmune diseases such as atopic dermatitis, ankylosing spondylitis, and rheumatoid arthritis. Compared to Upadacitinib, a leading marketed drug in its class, VC005 exhibits lower JAK2 inhibitory activity (based on in vitro kinase assay results), which may mitigate safety concerns associated with excessive JAK2 inhibition. Furthermore, since JAK1 synergizes with JAK3/TYK2 in multiple diseases, VC005's high selectivity for JAK1 over JAK2 may translate into superior clinical efficacy relative to other drugs in its class.
About Atopic Dermatitis (AD)
Atopic dermatitis is a chronic, relapsing, inflammatory skin disease characterized by dry skin, intense itching, and eczematous rashes, significantly impairing patients' quality of life. Epidemiologically, the global AD patient population is approximately 230 million, with an adult prevalence rate of 2%–8% in China, affecting over 70 million individuals. Among these, 67% are mild cases, and 33% are moderate-to-severe. Frost & Sullivan predicts that cases will grow at a compound annual rate of 1.7% from 2025 to 2030. Traditional treatments, such as corticosteroids, are associated with numerous adverse reactions and limited long-term benefits, making it challenging to achieve effective and stable control. In contrast, topical JAK1 small-molecule targeted inhibitors, as non-steroidal immunomodulators, may enhance treatment safety for mild-to-moderate AD patients while maintaining therapeutic efficacy.
Related News
31
2025
/
10
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced the completion of first patient enrollment in the Phase Ⅱ clinical trial of VC005 Tablets. This independently developed next-generation highly selective JAK1 inhibitor is being evaluated for the oral treatment of non-segmental vitiligo (NSV). The trial aims to assess the efficacy, safety, and PK profile of VC005 Tablets in Chinese adult NSV patients, providing a basis for the selection of dosage in subsequent clinical studies.
View Details
29
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has achieved a major milestone in the Phase Ⅲ clinical trial of VC005 Tablets – the company's independently developed second-generation highly selective JAK1 inhibitor for oral treatment of moderate-to-severe atopic dermatitis (AD) – with the successful completion of full patients enrollment. This multicenter, randomized, double-blind, placebo-controlled pivotal Phase Ⅲ study aims to further validate the efficacy and safety of VC005 Tablets in adult patients with moderate-to-severe AD. The smooth completion of enrollment marks a crucial step forward for this innovative drug towards clinical application.
View Details
15
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the official initiation of the Phase III clinical trial of VC005 Tablets—a self-developed second-generation highly selective JAK1 inhibitor—for the oral treatment of ankylosing spondylitis (AS). This marks the second Phase III clinical trial of VC005 Tablets, following the one for oral treatment of moderate-to-severe atopic dermatitis (AD), signifying that the AS indication has entered the confirmatory clinical research stage.
View Details
12
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) officially initiated the Phase II clinical trial of VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by the company, for a new oral indication – the treatment of non-segmental vitiligo (NSV).
View Details
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn